Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics
Egileak:
Ruso-Julve F, Pombero A, Pilar-Cuellar F, García-Díaz N, García-López R, Juncal-Ruiz M, Castro E, Díaz A, Vázquez-Bourgon J, García-Blanco A, Garro-Martínez E, Pisonero H, Estirado A, Ayesa-Arriola R, López-Gimenez J, Mayor Jr F, Valdizán E, Meana JJ, González-Maeso J, Martinez S, Vaqué JP, Crespo-Facorro B
